MXCT · NASDAQ
MaxCyte (MXCT) Stock Price & Fundamentals
MaxCyte (MXCT) closed at $428.95 on Oct 9, 2026, up 1.45% from the previous close of $422.80.
Share price, past year
1Y +37.83%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $428.95 |
| Sep 30, 2026 | $416.35 |
| Aug 31, 2026 | $394.06 |
| Jul 31, 2026 | $385.49 |
| Jun 30, 2026 | $361.92 |
| May 29, 2026 | $373.84 |
| Apr 30, 2026 | $317.09 |
| Mar 31, 2026 | $335.69 |
| Feb 27, 2026 | $313.97 |
| Jan 30, 2026 | $328.16 |
| Dec 31, 2025 | $329.27 |
| Nov 28, 2025 | $330.29 |
| Oct 31, 2025 | $308.85 |
Key statistics
- Market cap
- $45.53B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.36
- Revenue (TTM)
- $18.83M
- Net income (TTM)
- −$35.64M
- Shares outstanding
- 106.1M
- Dividend yield
- —
- 52-week range
- $301.78 – $428.95
MaxCyte's market cap is $45.53B, based on a share price of $428.95 and 106.1M shares outstanding as of Jun 30, 2026.
Financials
MaxCyte reported revenue of $20.96M for fiscal 2025, down 5.66% from fiscal 2024.
MaxCyte reported a net loss of $44.63M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $20.96M | −5.7% | −$44.63M | −213.0% | −$0.42 | −$36.18M |
| FY2024ended Dec 31, 2024 | $22.22M | +13.9% | −$41.06M | −184.8% | −$0.39 | −$29.26M |
| FY2023ended Dec 31, 2023 | $19.50M | −32.2% | −$37.92M | −194.5% | −$0.37 | −$25.39M |
| FY2022ended Dec 31, 2022 | $28.75M | +33.3% | −$23.57M | −82.0% | −$0.23 | −$33.26M |
| FY2021ended Dec 31, 2021 | $21.57M | +39.6% | −$19.08M | −88.5% | −$0.21 | −$14.51M |
| FY2020ended Dec 31, 2020 | $15.45M | +16.6% | −$11.82M | −76.5% | −$0.17 | −$10.85M |
| FY2019ended Dec 31, 2019 | $13.26M | — | −$12.90M | −97.3% | −$0.23 | −$10.07M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $4.94M | −$8.87M | −$0.08 |
| Q1 FY2026ended Mar 31, 2026 | $4.50M | −$4.75M | −$0.04 |
| Q4 FY2025ended Dec 31, 2025 | $4.79M | −$9.60M | — |
| Q3 FY2025ended Sep 30, 2025 | $4.60M | −$12.42M | −$0.12 |
| Q2 FY2025ended Jun 30, 2025 | $5.82M | −$12.36M | −$0.12 |
| Q1 FY2025ended Mar 31, 2025 | $5.74M | −$10.26M | −$0.10 |
| Q4 FY2024ended Dec 31, 2024 | $6.05M | −$10.60M | — |
| Q3 FY2024ended Sep 30, 2024 | $5.61M | −$11.56M | −$0.11 |
Company profile
- Name
- MaxCyte, Inc.
- Ticker
- MXCT
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Services-Commercial Physical & Biological Research
- Headquarters
- 9713 Key West Avenue,, Suite 400, Rockville, MD 20850
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001287098
Recent SEC filings
- Aug 13, 2026
- Aug 12, 2026
- Jun 17, 2026
- Jun 16, 2026
- May 13, 2026
- May 12, 2026
- Mar 27, 2026
- Mar 25, 2026
Frequently asked questions
What is MaxCyte's stock price?
MaxCyte (MXCT) closed at $428.95 on Oct 9, 2026, up 1.45% from the previous close of $422.80.
What is MaxCyte's market cap?
MaxCyte's market cap is $45.53B, based on a share price of $428.95 and 106.1M shares outstanding as of Jun 30, 2026.
How much revenue does MaxCyte make?
MaxCyte reported revenue of $20.96M for fiscal 2025, down 5.66% from fiscal 2024.
Does MaxCyte pay a dividend?
MaxCyte's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from MaxCyte, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures